AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Recursion Pharmaceuticals (RXRX) reached $4.32 at the closing of the latest trading day, reflecting a -3.36% change compared to its last close.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The book takes a close look at how knowledge spreads among people and throughout societies. For example: “The Emperor’s New Clothes.” In this Hans Christian Andersen story, con men tell a vain emperor ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...